Drug Profile
BI 811283
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 31 Aug 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Germany (IV)
- 31 Aug 2015 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy) in Germany (IV)
- 25 Nov 2011 Boehringer Ingelheim completes enrolment in its Phase-I/IIa trial for Acute myeloid leukaemia in Germany (NCT00632749)